BCL7A 低表达预示卵巢癌预后不良。
Low BCL7A expression predicts poor prognosis in ovarian cancer.
机构信息
Department of Gynaecology and Obstetrics, China-Japan Union Hospital of Jilin University, 126 Xiantai Street, Changchun, 130033, People's Republic of China.
Department of Breast Surgery, China-Japan Union Hospital of Jilin University, 126 Xiantai Street, Changchun, 130033, People's Republic of China.
出版信息
J Ovarian Res. 2019 May 10;12(1):41. doi: 10.1186/s13048-019-0518-0.
BACKGROUND AND OBJECTIVE
Ovarian cancer is a common gynaecological cancer with a poor prognosis that poses a serious threat to human life and health. It is essential to explore the possible prognostic biomarkers of ovarian cancer. As an important tumour suppressor gene, BCL7A actively participates in the growth of tumours. We aimed to study the prognostic role of BCL7A in ovarian cancer.
RESULTS
Through data mining of RNAseq data from the Cancer Genome Atlas database (TCGA), we explored the clinical relevance of BCL7A mRNA expression. As a result, we found that BCL7A is expressed at low levels in ovarian cancer tissues and is correlated with survival status. Survival analysis showed that, compared with those who had higher levels of BCL7A expression, patients with ovarian cancer and low levels of BCL7A generally had shorter overall/relapse-free survival times. Cox regression models showed that low BCL7A expression could be used as an independent prognostication factor for ovarian cancer patients.
CONCLUSIONS
Low BCL7A expression is an independent risk factor for poor prognosis in ovarian cancer patients.
背景与目的
卵巢癌是一种常见的妇科癌症，预后较差，严重威胁人类生命健康。探索卵巢癌可能的预后生物标志物至关重要。BCL7A 作为一个重要的肿瘤抑制基因，积极参与肿瘤的生长。我们旨在研究 BCL7A 在卵巢癌中的预后作用。
结果
通过对癌症基因组图谱数据库（TCGA）的 RNAseq 数据进行数据挖掘，我们探讨了 BCL7A mRNA 表达的临床相关性。结果发现，BCL7A 在卵巢癌组织中表达水平较低，与生存状态相关。生存分析表明，与 BCL7A 表达水平较高的患者相比，BCL7A 水平较低的卵巢癌患者的总生存期/无复发生存期通常较短。Cox 回归模型表明，低 BCL7A 表达可作为卵巢癌患者独立的预后预测因素。
结论
低 BCL7A 表达是卵巢癌患者预后不良的独立危险因素。
Zotero 插件